Alfred Sommer Receives The Bristol-Myers Squibb/Mead Johnson Award For Distinguished Achievement In Nutrition Research

15-Oct-2001 - EVANSVILLE, INDIANA (October 12, 2001) -- Alfred Sommer, M.D., M.H.S., is the recipient of the 21st Annual Bristol-Myers Squibb/Mead Johnson Award for Distinguished Achievement in Nutrition Research for his contributions to our understanding of the origin, magnitude and control of nutritional ...

FDA Advisory Committee issues split decision on recommendation to approve Diovan® (valsartan) for heart failure indication

15-Oct-2001 - Basel / East Hanover, 12 October 2001 – Novartis' Pharmaceuticals affiliate in the US, Novartis Pharmaceuticals Corporation, announced yesterday that the Cardiovascular and Renal Drugs Advisory Committee to the US Food and Drug Administration (FDA) has issued a four-to-four split decision about ...

bioLeads collaborats with Biofrontera Pharmaceuticals AG

12-Oct-2001 - Heidelberg/Leverkusen: bioLeads GmbH and Biofrontera Pharmaceuticals AG announced today that they have entered into a strategic alliance to discover new lead compounds for CNS diseases and develop them to the clinical trials level. The initial focus of the collaboration will be on the medical ...

Biosearch Italia announces North American licensing agreement

Biosearch Italia SpA has signed a licensing agreement for North American rights to its Phase III product Ramoplanin with Genome Therapeutics Corp.

10-Oct-2001 - Ramoplanin is a novel antibiotic for the prevention of bloodstream infections caused by vancomycin-resistant enterococci (VRE), an increasingly prevalent bacteria in certain at-risk groups, such as immunocompromised patients. If approved, Ramoplanin will be the first available antibiotic ...